Risedronate Sodium Delayed-release Tablets, 35 mg, Once-a-Week, 1 tablet per blister (NDC 0093-5509-19), packaged in 4 blisters per carton (NDC 0093-5509-44), Rx only, TEVA PHARMACEUTICALS USA, INC., North Wales, PA 19454.
Published January 25, 2017 · Recall initiated: December 1, 2016
Summary
FDA records drug Class III recall D-0431-2017, published January 25, 2017 and initiated December 1, 2016. Recalling firm: Teva Pharmaceuticals USA; Status: Terminated; Reported quantity: 6,800 cartons; Lot: Lot # 34027040A; Exp 10/17. Class III means the product is not likely to cause adverse health consequences.
Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.
What's the hazard
Failed Dissolution Specifications
What to do
Voluntary: Firm initiated · Letter
Get an email when a new FDA recall like this is published
Free. We only write when there's a new recall that matches. Unsubscribe in one click.
Recall details
- Manufacturer
- Teva Pharmaceuticals USA
- Distributor
- Nationwide in the USA and Puerto Rico
- Lot
- Lot # 34027040A; Exp 10/17
- Risk classification
- Class III
- Area (FDA)
- drug
- Country
- United States
Related recalls
- FDAMimvey (estradiol and norethindrone acetate tablets USP), 1 mg/0.5 mg, packaged in cartons of 28 Tablets, RxFebruary 9, 2022
- FDADoxylamine Succinate and Pyridoxine Hydrochloride Delayed-Release Tablets 10 mg/10 mg, 100-count bottle, RxFebruary 9, 2022
- FDAMimvey (estradiol and norethindrone acetate tablets USP) 1 mg/0.5 mg, packaged in cartons of 28 Tablets, RxFebruary 9, 2022
- FDATretinoin Capsules, 10 mg, 100 count bottle, Rx Only, Teva Pharmaceuticals USA, Inc., North Wales, PA 19454,February 9, 2022
- FDAPentasa (mesalamine) Controlled-Release Capsules, 250 mg, 240 count bottle, Rx only, Manufactured for Shire USJanuary 25, 2017
- FDAOPT Croutons is a synthetic bone substitute designed for the repair of bony defects and is made of pureJanuary 18, 2017
Questions about this recall
Was Risedronate Sodium Delayed-release Tablets, 35 mg, Once-a-Week, 1 tablet per blister (NDC 0093-5509-19), packaged in 4 blisters per carton (NDC 0093-5509-44), Rx only, TEVA PHARMACEUTICALS USA, INC., North Wales, PA 19454. recalled?
Yes. FDA published recall D-0431-2017 on January 25, 2017. Reported hazard: Failed Dissolution Specifications
What should I do if I have this product?
Voluntary: Firm initiated · Letter